Last, atherosclerosis development and cardiovascular safety can be evaluated in the E3L.GK+/− model, which is especially interesting regarding the currently unknown mechanisms by which glucose-lowering agents (e.g., empagliflozin, liraglutide, and semaglutide) improve CV outcome [50–52]. The gene discussed is GK; the disease is atherosclerosis.